Teva's Lucky Number Seven: Analysis Supports Shorter Exclusivity For Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
Paper by AEI fellow Brill challenges the assumptions in the 16-year estimate from Duke's Grabowski.